biostudies-literatureUnknown13(3)Keating CVertex Pharmaceuticals IncorporatedNIDDK NIH HHSThe Lancet. Respiratory medicine256-271https://www.ebi.ac.uk/biostudies/studies/S-EPMC12184100biostudies-literatureVanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.PMC12184100P30 DK089507Hoppe JVermeulen FShkolnik BOlesen HKherani TDurieu IPatel NReyes SBurr LLiou TChatziagorou EChmiel JForseen CSole Jover ABakkeheim EParkins MElidemir OJain RLinnane BLaki IJohannes JJain MStahl MSchaeffer DFloreth TMulrennan STaylor-Cousar JMichelson PO'Carroll MLeroy STeneback CUrquhart DBilodeau LSchwarz CAhluwalia NSermet-Gaudelus IDacco VEpaud RLindberg UHoudouin VOwens LMondejar-Lopez PQuon BPeckham DQuintana-Gallego EWong JSears ENicholson JMSzepfalusi ZSivam SPlant BGreen DKnoop CRamsey BLuna CTaccetti GMarguet CBarrios CMcCoy KUluer ARuddy JBarry PHalasz APancham KLivingston FMukadam ZGramegna ABarbosa TBode SMorrissey BCallison JMazurek HGrenet DKremer TSalvatore DBraun AEber EEscobar HMacGregor GChiron RMehdi NDaines CTatopoulos AKennedy JKrick SWurth MWelter JFabrizzi BNaehrig SVX20-121-103 Study GroupWithers NJohnson LPressler TWallace JElnazir BRingshausen FAtkinson JO'Sullivan BRoukema JPoplawska KAltenburg JBui SWeiss LDe Monestrol IJia SSapiejka EMcKone EQuick BSands DVan Braeckel EWilhelm AZahigian RKeens TTissot ABagheri-Potthoff ACols Roig MLedson MDillenhofer SKoser USosnay PRGoss CScher HCasserly BStehling FHolliday ZFortner CDubin PMoffett KMessore BTolle JHilliard TMermis JMartin HHebestreit HEpton MFiel SLysinger JFilbrun AKamphuis LSimmonds NFischer RTremblay FCastellani CBillings JKlingsberg RMueller GSutharsan SSinger JHenderson DBlitz Castro EDoe SFroh DDesai MEngan MFajac ICohen-Cymberknoh MOmlor GEgan MLegg JStudnicka MDittrich AMMaitra AManika KSchellhase DHorsley AByrnes CWeiner DFischer Biner RChilvers MYonker LCalimano FRamel SRen Cvan der Ent KBraun ATCox DKeating CRuiz FGohy STrimble AKotsimbos TFrederick CRoberts JCipolli MLee TVanderhelst ESauty ALopez Neyra AHaworth CMiddleton PCarroll MLinnemann RWWang JBrown CDiMango EMankikian JEfrati OHomola LTupayachi Ortiz MGClements BWaller MDuckers JGleiber WLambert AVX20-121-102 Study GroupTullis ETirakitsoontorn PWainwright CDrevinek PLe Rouzic OTrillo-Alvarez CLam AGilljam MNair NAzevedo PMoeller APrais Dvan der Meer RGartner SMarion CWilliamson MReix PAmorim ALinnemann RMillard SAsensio de la Cruz OStaples HLands LMall MADeschamps ALapey ARobinson PKing CRuppel RBrown PTaylor-Cousar JLMcKone EFYonker LMLorenz MAppelt DBrown SfalseVanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.2025-01-01T00:00:00Z2025 Mar2026-06-03T06:56:40.414Z2026-04-25T03:22:09.822ZS-EPMC121841003975642410.1016/S2213-2600(24)00411-9